Positive News Sentiment NASDAQ:EYPT EyePoint Pharmaceuticals - EYPT Short Interest Ratio & Short Volume Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding EyePoint Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $2.66 +0.38 (+16.67%) (As of 03/27/2023 12:09 PM ET) Add Compare Share Share Today's Range$2.28▼$2.7650-Day Range$2.28▼$5.0452-Week Range$2.19▼$13.05Volume377,657 shsAverage Volume286,020 shsMarket Capitalization$91.24 millionP/E RatioN/ADividend YieldN/APrice Target$23.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media EyePoint Pharmaceuticals Short Interest DataCurrent Short Volume2,790,000 sharesPrevious Short Volume2,070,000 sharesChange Vs. Previous Month+34.78%Dollar Volume Sold Short$6.67 millionShort Interest Ratio / Days to Cover10.0Last Record DateMarch 15, 2023Outstanding Shares34,300,000 sharesFloat Size25,710,000 sharesShort Percent of Float10.85%Today's Trading Volume377,657 sharesAverage Trading Volume286,020 sharesToday's Volume Vs. Average32.04% Short Selling EyePoint Pharmaceuticals ? Sign up to receive the latest short interest report for EyePoint Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatEYPT Short Interest Over TimeEYPT Days to Cover Over TimeEYPT Percentage of Float Shorted Over Time EyePoint Pharmaceuticals (NASDAQ:EYPT) Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/15/20232,790,000 shares $6.67 million +34.8%10.9%10 $2.39 2/28/20232,070,000 shares $6.91 million No Change8.1%8.1 $3.34 2/15/20232,070,000 shares $7.66 million -4.2%8.1%8.5 $3.70 1/31/20232,160,000 shares $10.07 million +6.9%8.6%9.3 $4.66 1/15/20232,020,000 shares $10.18 million +13.5%8.0%9.4 $5.04 12/30/20221,780,000 shares $6.23 million +6.0%7.1%12.3 $3.50 12/15/20221,680,000 shares $4.50 million -2.9%6.7%11.6 $2.68 11/30/20221,730,000 shares $5.54 million -3.4%6.9%13.6 $3.20 11/15/20221,790,000 shares $7.91 million -9.1%7.1%14.1 $4.42 10/31/20221,970,000 shares $10.64 million -1.5%N/A16.1 $5.40 10/15/20222,000,000 shares $11.20 million -1.5%7.7%14.3 $5.60 9/30/20222,030,000 shares $16.06 million -0.5%7.8%12.5 $7.91 9/15/20222,040,000 shares $16.30 million +0.5%7.9%12.7 $7.99 8/31/20222,030,000 shares $20.30 million +1.5%7.8%12.7 $10.00 8/15/20222,000,000 shares $22.24 million -8.3%7.7%12.8 $11.12 7/31/20222,180,000 shares $19.90 million +7.4%8.3%13.8 $9.13 7/15/20222,030,000 shares $20.12 million +1.0%7.8%14.4 $9.91 6/30/20222,010,000 shares $15.82 million +2.0%7.7%16.8 $7.87 6/15/20221,970,000 shares $15.62 million -5.3%7.5%16.7 $7.93 5/31/20222,080,000 shares $20.07 million -3.3%8.0%16 $9.65 5/15/20222,150,000 shares $21.26 million -1.4%8.2%14.1 $9.89 4/30/20222,180,000 shares $24.63 million +0.5%8.3%13.4 $11.30 4/15/20222,170,000 shares $27.54 million +0.5%8.3%11.9 $12.69 3/31/20222,160,000 shares $26.24 million +4.9%8.3%9.6 $12.15 3/15/20222,060,000 shares $24.82 million +3.0%7.9%7.9 $12.05 2/28/20222,000,000 shares $19.90 million +3.6%7.7%7.2 $9.95 2/15/20221,930,000 shares $19.59 million -2.5%7.4%6.6 $10.15 1/31/20221,980,000 shares $18.55 million -8.3%7.6%2.4 $9.37 1/15/20222,160,000 shares $21.45 million +11.3%N/A2.7 $9.93 12/31/20211,940,000 shares $23.75 million +0.5%7.4%2.5 $12.24 12/15/20211,930,000 shares $28.27 million -3.5%7.4%2.6 $14.65 11/30/20212,000,000 shares $31.60 million +98.0%8.1%2.9 $15.80 11/15/20211,010,000 shares $14.44 million -34.0%4.2%1.5 $14.30 10/29/20211,530,000 shares $17.55 million +10.9%7.3%11 $11.47 10/15/20211,380,000 shares $15.79 million +0.7%6.6%12.1 $11.44 9/30/20211,370,000 shares $14.28 million -3.5%6.5%11.3 $10.42 9/15/20211,420,000 shares $14.31 million +2.9%6.8%8.4 $10.08 8/31/20211,380,000 shares $15.10 million +4.6%6.6%8.2 $10.94 8/13/20211,320,000 shares $13.66 million -4.4%6.3%8 $10.35 7/30/20211,380,000 shares $11.34 million +5.3%6.6%8.1 $8.22 EYPT Short Interest - Frequently Asked Questions What is EyePoint Pharmaceuticals' current short interest? Short interest is the volume of EyePoint Pharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of February 28th, traders have sold 2,070,000 shares of EYPT short. 8.13% of EyePoint Pharmaceuticals' shares are currently sold short. Learn More on EyePoint Pharmaceuticals' current short interest. What is a good short interest ratio for EyePoint Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. EYPT shares currently have a short interest ratio of 8.0. Learn More on EyePoint Pharmaceuticals's short interest ratio. Which institutional investors are shorting EyePoint Pharmaceuticals? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of EyePoint Pharmaceuticals: Susquehanna International Group LLP, Group One Trading L.P., and Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for EyePoint Pharmaceuticals? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 8.13% of EyePoint Pharmaceuticals' floating shares are currently sold short. What is EyePoint Pharmaceuticals' float size? EyePoint Pharmaceuticals currently has issued a total of 34,300,000 shares. Some of EyePoint Pharmaceuticals' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. EyePoint Pharmaceuticals currently has a public float of 25,470,000 shares. How does EyePoint Pharmaceuticals' short interest compare to its competitors? 8.13% of EyePoint Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the industry of "analytical instruments" compare to EyePoint Pharmaceuticals: Berkeley Lights, Inc. (9.05%), Singular Genomics Systems, Inc. (3.93%), Rapid Micro Biosystems, Inc. (0.12%), Accelerate Diagnostics, Inc. (4.77%), IsoPlexis Co. (0.74%), Standard BioTools Inc. (3.96%), Seer, Inc. (6.64%), Akoya Biosciences, Inc. (2.93%), Cue Health Inc. (3.39%), and Nautilus Biotechnology, Inc. (1.80%). Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Suncor Energy Inc. ($3.27 billion), Occidental Petroleum Co. ($2.77 billion), Coinbase Global, Inc. ($2.25 billion), T. Rowe Price Group, Inc. ($2.23 billion), Paramount Global ($1.92 billion), Etsy, Inc. ($1.75 billion), Voya Financial, Inc. ($1.74 billion), CarMax, Inc. ($1.62 billion), Old Dominion Freight Line, Inc. ($1.62 billion), and Royal Caribbean Cruises Ltd. ($1.39 billion). View all of the most shorted stocks. What does it mean to sell short EyePoint Pharmaceuticals stock? Short selling EYPT is an investing strategy that aims to generate trading profit from EyePoint Pharmaceuticals as its price is falling. EYPT shares are trading down $0.05 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against EyePoint Pharmaceuticals? A short squeeze for EyePoint Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of EYPT, which in turn drives the price of the stock up even further. How often is EyePoint Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including EYPT, twice per month. The most recent reporting period available is February, 28 2023. More Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:EYPT) was last updated on 3/27/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.